This is a routine CEO compensation grant with no immediate trading signal. The performance hurdles are extremely high (3x-8x current stock price), making dilution unlikely in the near term. Monitor next quarterly results for pipeline progress that could drive the stock toward the first vesting threshold.
AGEN drugs
AGEN drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 13 $7.00entry
- T+1 · 3mo ago +4.57%α +4.77% · $7.32
- T+5 · 3mo ago +7.00%α +8.96% · $7.49
- T+20 · 2mo ago −0.86%α +0.89% · $6.94
- T+60 · 11d ago −1.43%α +3.81% · $6.90
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Agenus granted Chairman/CEO Garo Armen a one-time performance-based stock option award of 1,971,500 options with a $7.78 exercise price (above the current closing price). The options vest in five tranches tied to stock price targets of 3x to 8x the exercise price, with a minimum three-year service requirement. This is a routine compensatory arrangement with no departure or financial impact, making it neutral for the stock.
Key Facts
- CEO Garo Armen received 1,971,500 performance-based stock options with a 10-year term
- Exercise price set at $7.78 per share, above the August 10, 2026 closing price
- Options vest in five tranches at 3x, 4x, 5x, 6x, and 8x the measurement price
- Minimum three-year service requirement; no acceleration on change in control
- Award approved by Compensation Committee with independent consultant Aon Talent Solutions
Financial Impact
No immediate financial impact; potential dilution of up to 1,971,500 shares if all options vest and are exercised, but vesting requires stock price appreciation to $23.34-$62.24 per share
Risk Factors
- Dilution risk if stock appreciates significantly and options vest
- No material change to business fundamentals or financial outlook
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-347518 |
| Document: 0001193125-26-347518-index-headers.html | 0001193125-26-347518 |
| Document: 0001193125-26-347518-index.html | 0001193125-26-347518 |
| Document: 0001193125-26-347518.txt | 0001193125-26-347518 |
Track record
12 reports on AGEN
3 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +138.65% at T+60 after the May 11, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry price pending
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $6.97 Now $6.29 −9.76% settles Feb 12
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $6.44 Now $6.29 −2.33% settles Feb 3
- Aug 12, 202613w ago 8-K Neutral 2/10 Viewing Entry $7.00 to $6.90 Now $6.29 −10.14% ▼ −1.43% +3.81% vs SPY
- Aug 12, 202613w ago Institutional Cluster Mixed 4/10 Entry $6.90 to $6.97 Now $6.29 −8.84% ▲ +1.01% +5.89% vs SPY
- Aug 7, 202614w ago S-3 Bearish 7/10 Entry $7.00 to $6.76 Now $6.29 +10.14% ▲ +3.43% +1.53% vs SPY
- Aug 6, 202614w ago 8-K Neutral 5/10 Entry $7.49 to $6.84 Now $6.29 −16.02% ▼ −8.68% −7.01% vs SPY
- Jul 17, 202617w ago S-3 Bearish 5/10 Entry $4.97 to $6.95 Now $6.29 −26.56% ▼ −39.84% −35.00% vs SPY
- Jul 13, 202618w ago 8-K Bearish 6/10 Entry $6.12 to $7.49 Now $6.29 −2.78% ▼ −22.39% −18.39% vs SPY
- May 13, 202626w ago DEFA14A Neutral 4/10 Entry $3.47 to $6.96 Now $6.29 +81.27% ▲ +100.58% +96.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers